Regeneron, Sanofi: COPD Drug Itepekimab Meets Primary Goal In 1 Phase 3 Trial, But Fails In Another

Regeneron and Sanofi's Itepekimab Phase 3 trial, AERIFY-1, met its primary endpoint, demonstrating a 27% reduction in moderate or severe COPD exacerbations compared to placebo in former smokers; however, the AERIFY-2 trial failed to meet the same endpoint, despite showing early benefits. The companies are analyzing the data and plan to discuss the results with regulatory authorities to determine future steps for the drug, which is also being investigated for other respiratory conditions.

Analysis

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) reported mixed Phase 3 trial results for Itepekimab in chronic obstructive pulmonary disease (COPD). The AERIFY-1 trial successfully met its primary endpoint, demonstrating a statistically significant and clinically meaningful 27% reduction in moderate or severe acute exacerbations at 52 weeks in former smokers compared to placebo. This positive outcome was observed across both dosing regimens (every two weeks and every four weeks) and was independent of eosinophilic phenotype. However, the second Phase 3 trial, AERIFY-2, failed to meet the same primary endpoint, despite showing some benefit earlier in the trial. The companies indicated that the overall number of exacerbations observed was lower than prospectively anticipated, potentially due to enrollment occurring during the COVID-19 pandemic, which consequently reduced the statistical power of both studies. Itepekimab was reported as generally well-tolerated, with a safety profile consistent with prior trials. Regeneron and Sanofi are currently reviewing the complete dataset from both trials and plan to discuss these findings with regulatory authorities to determine future steps for Itepekimab in COPD. The drug continues to be evaluated in other respiratory indications, and these mixed COPD results introduce a degree of uncertainty regarding its path to market for this specific condition.

Key Decisions for Investors

• Investors should closely monitor forthcoming announcements from Regeneron and Sanofi regarding their discussions with regulatory authorities and the planned next steps for Itepekimab in COPD, as this will be critical in assessing its future viability for this indication.
• Given the conflicting trial outcomes, with AERIFY-1 showing a 27% reduction in exacerbations but AERIFY-2 failing, the path forward for Itepekimab in COPD is uncertain; the lower-than-anticipated exacerbation rates impacting trial power also warrant careful consideration of the data's robustness.
• The ongoing development of Itepekimab in other respiratory diseases, such as chronic rhinosinusitis and non-cystic fibrosis bronchiectasis, remains a key factor, and progress in these areas could potentially offset the mixed results in the COPD program.